BMY
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$63.06
+0.35%0
Insider buys (3m)
2
Insider sells (3m)
-$437.2K
Net value (3m)
+14.7%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Massacesi Cristian · officer: EVP,Chief Med Offr,Head of Dev | Sale | 6,249 | $65 |
| Sep 3, 2026 | Short Bartie Wendy · officer: EVP, Corporate Affairs | M-Exempt | 1,236 | $67 |
| Sep 3, 2026 | Short Bartie Wendy · officer: EVP, Corporate Affairs | F-InKind | 633 | $67 |
| Aug 26, 2026 | Holzer Phil M · officer: SVP and Controller | Sale | 500 | $68 |
| Aug 4, 2026 | Massacesi Cristian · officer: EVP,Chief Med Offr,Head of Dev | F-InKind | 26,175 | $65 |
| Aug 4, 2026 | Massacesi Cristian · officer: EVP,Chief Med Offr,Head of Dev | M-Exempt | 51,172 | $0.00 |
| Aug 4, 2026 | Gallman Cari · officer: EVP, General Counsel | F-InKind | 543 | $65 |
| Aug 4, 2026 | Gallman Cari · officer: EVP, General Counsel | M-Exempt | 1,061 | $0.00 |
| Jul 2, 2026 | Samuels Theodore R. II · director | A-Award | 889 | $0.00 |
| Jul 2, 2026 | McMullen Michael R. · director | A-Award | 607 | $0.00 |
| Jul 2, 2026 | Arduini Peter J · director | A-Award | 607 | $0.00 |
| Jul 2, 2026 | Rice Derica W · director | A-Award | 673 | $0.00 |
| Jul 2, 2026 | YALE PHYLLIS R · director | A-Award | 607 | $0.00 |
| Jun 16, 2026 | Haller Julia A · director | M-Exempt | 20,460 | $54 |
| Jun 5, 2026 | Short Bartie Wendy · officer: EVP, Corporate Affairs | M-Exempt | 8,040 | $0.00 |
| Jun 5, 2026 | Short Bartie Wendy · officer: EVP, Corporate Affairs | F-InKind | 3,876 | $55 |
| May 5, 2026 | Lenkowsky Adam · officer: EVP, Chief Commercial Officer | M-Exempt | 1,373 | $0.00 |
| May 5, 2026 | Lenkowsky Adam · officer: EVP, Chief Commercial Officer | F-InKind | 599 | $58 |
| Apr 2, 2026 | Rice Derica W · director | A-Award | 639 | $0.00 |
| Apr 2, 2026 | YALE PHYLLIS R · director | A-Award | 577 | $0.00 |
| Apr 2, 2026 | Elkins David V · officer: EVP, Chief Financial Officer | Sale | 4,481 | $62 |
| Apr 2, 2026 | Shanahan Karin · officer: EVP, Chief Supply Chain & Ops | F-InKind | 1,692 | $62 |
| Apr 2, 2026 | Samuels Theodore R. II · director | A-Award | 845 | $0.00 |
| Apr 2, 2026 | McMullen Michael R. · director | A-Award | 577 | $0.00 |
| Apr 2, 2026 | Arduini Peter J · director | A-Award | 577 | $0.00 |
| Apr 2, 2026 | Shanahan Karin · officer: EVP, Chief Supply Chain & Ops | M-Exempt | 3,307 | $0.00 |
| Apr 2, 2026 | Elkins David V · officer: EVP, Chief Financial Officer | Sale | 25,519 | $62 |
| Mar 12, 2026 | Hoch Lynelle · officer: President, Cell Therapy Org. | F-InKind | 912 | $60 |
| Mar 12, 2026 | Hoch Lynelle · officer: President, Cell Therapy Org. | F-InKind | 212 | $60 |
| Mar 12, 2026 | Plenge Robert M · officer: EVP, Chief Research Officer | M-Exempt | 1,107 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 450Increased 2041Reduced 1922Sold out 173
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 180,384,994 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 171,682,888 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 133,337,856 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 132,320,240 | May 15, 2026 |
| STATE STREET CORP | Increased | 102,408,940 | Aug 7, 2026 |
| STATE STREET CORP | Increased | 98,564,914 | May 15, 2026 |
| JPMORGAN CHASE & CO | Increased | 92,475,194 | May 13, 2026 |
| JPMORGAN CHASE & CO | Reduced | 71,713,442 | Aug 12, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | Increased | 67,595,177 | Aug 14, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | Reduced | 61,115,373 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 56,443,077 | Aug 12, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 55,286,174 | May 15, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 46,873,015 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 46,230,155 | May 8, 2026 |
| NORGES BANK | New Position | 36,866,658 | Aug 12, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 10, 2026